Ultragenyx Pharmaceutical Inc represents values of innovation, commitment, and compassion in the field of biopharmaceuticals. The company strives to develop transformative therapies for rare and ultra-rare diseases, aiming to improve the lives of patients with limited treatment options. With a focus on rare genetic diseases, Ultragenyx is dedicated to advancing research and delivering breakthrough therapies that address unmet medical needs. By investing in cutting-edge science and leveraging strategic partnerships, Ultragenyx aims to make a positive impact in the lives of patients and their families.

Ultragenyx Pharmaceutical Inc is primarily present in the United States.

Some significant milestones achieved by Ultragenyx Pharmaceutical Inc include the approval of their first therapy, Mepsevii, by the U.S. FDA for the treatment of Mucopolysaccharidosis VII, a rare genetic disorder. They also successfully launched Crysvita, a treatment for X-linked hypophosphatemia, in the United States and Europe. Ultragenyx Pharmaceutical Inc has expanded its pipeline with multiple ongoing clinical trials for potential therapies aimed at rare diseases, including DTX401 for the treatment of Ornithine Transcarbamylase Deficiency. With a dedication to developing innovative therapies, Ultragenyx Pharmaceutical Inc continues to make advancements in the field of rare diseases.

Ultragenyx Pharmaceutical Inc., headquartered in Novato, California, is a biopharmaceutical company focused on the development and commercialization of innovative treatments for rare genetic diseases. Founded in 2010, Ultragenyx has quickly established itself as a leader in the field of rare diseases, with a mission to bring hope to patients and their families. The company's extensive research and development efforts have resulted in the creation of a robust pipeline of potential therapies targeting different indications. Ultragenyx has also fostered collaborations with academic institutions and industry partners to further enhance its capabilities in discovering breakthrough treatments. With a strong commitment to improving patients' lives, Ultragenyx continues to drive innovation in the field of rare diseases.

Ultragenyx Pharmaceutical Inc faces competition in the market from several other pharmaceutical companies. Some of its main competitors include BioMarin Pharmaceutical Inc, Regeneron Pharmaceuticals Inc, and Alexion Pharmaceuticals Inc. These companies operate in the same industry and develop similar innovative therapies and treatments. However, Ultragenyx Pharmaceutical Inc distinguishes itself through its focus on rare and ultra-rare diseases, providing unique solutions for patients in need.

Ultragenyx Pharmaceutical Inc is primarily active in the biotechnology industry.

The business model of Ultragenyx Pharmaceutical Inc. revolves around developing and commercializing innovative treatments for rare and ultra-rare genetic diseases. Ultragenyx focuses on identifying these diseases with high unmet medical needs and strives to provide patients with effective therapies. The company aims to conduct extensive research and clinical trials to obtain regulatory approvals for its products. Ultragenyx also collaborates with external partners for research, development, and commercialization activities. By focusing on rare diseases, Ultragenyx aims to make a significant impact on the lives of patients and their families while delivering sustainable value to its stakeholders.

P/E odnos Ultragenyx Pharmaceutical iznosi -6,87.

KUV kompanije Ultragenyx Pharmaceutical iznosi 7,42.

AlleAktien kvalitativni skor za Ultragenyx Pharmaceutical je 6/10.

očekivana Ultragenyx Pharmaceutical promet je 547,23 mil. USD.

Dobit očekivana Ultragenyx Pharmaceutical je -591,17 mil. USD.

Ultragenyx Pharmaceutical Inc is a US biotechnology company specializing in the development and commercialization of therapies for rare genetic diseases. The company is headquartered in Novato, California. Ultragenyx represents a part of the rapidly growing biotechnology industry driven by groundbreaking scientific advances and the demand for innovative treatment options. The company's core business includes research, development, and marketing of drugs for the treatment of rare genetic diseases. Ultragenyx focuses on diseases that have limited or no treatment options available. In this area, the company holds a leading position among biotech start-ups. The company's portfolio currently includes several products, including the enzyme replacement therapy classic Dojolvi, used for long-chain fatty acid oxidation disorders, and Crysvita, a medication for the treatment of a rare bone disease. Other products are still in clinical development. In recent years, Ultragenyx has also invested in gene therapies. The company is working on a novel gene therapy for the treatment of a rare, life-threatening metabolic disorder called GSD1a. A possible gene therapy could provide affected patients with lifelong and life-changing treatment. As a biotechnology company, Ultragenyx relies on partnerships and collaborations. The company has previously entered into strategic partnerships with other biotechnology and pharmaceutical companies to advance the development and commercialization of its products. The business model of Ultragenyx combines research, development, and marketing and aims to treat rare genetic diseases with limited or no current treatment options. Thanks to its focus on genetic diseases and gene therapies, as well as its partnerships, the company stands as one of the most promising biotech start-ups in the industry. In summary, the success model of Ultragenyx lies in identifying market gaps for the treatment of rare genetic diseases. Thanks to its developments in the field of enzyme replacement therapies and gene therapies, the company has established itself as a significant player in the biotechnology industry. The company pursues future opportunities through additional treatment options for rare genetic diseases, utilizing a business strategy based on partnerships and collaborations.

Ultragenyx Pharmaceutical isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Ultragenyx Pharmaceutical trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Ultragenyx Pharmaceutical je US90400D1081.

WKN od Ultragenyx Pharmaceutical je A1XCY0.

Oznaka za praćenje akcija kompanije Ultragenyx Pharmaceutical je RARE.

U poslednjih 12 meseci, Ultragenyx Pharmaceutical je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Ultragenyx Pharmaceutical će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Ultragenyx Pharmaceutical trenutno iznosi .

Ultragenyx Pharmaceutical isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Ultragenyx Pharmaceutical je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Ultragenyx Pharmaceutical se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Ultragenyx Pharmaceutical od 9. 9. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 9. 9. 2024..

Isplata poslednje dividende izvršena je 9. 9. 2024..

U godini 2023 kompanija Ultragenyx Pharmaceutical je isplatila 0 USD kao dividende.

Dividende od Ultragenyx Pharmaceutical se isplaćuju u USD.